Breast Cancer News Military pilots and the ground crews who fuel and maintain their aircraft have higher rates of certain cancers, a new study shows.
Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.
Among African-American cancer survivors, experiencing discrimination is associated with frailty, a study suggests.
Low-dose tamoxifen reduces the risk of breast cancer among patients with intraepithelial neoplasia for several years, data suggest.
Researchers are conducting a phase 2 trial to test pembrolizumab and tamoxifen, with or without vorinostat, in patients with ER+ breast cancer.
Researchers are testing valemetostat plus trastuzumab deruxtecan in patients with HER2-low/ultra-low/null metastatic breast cancer.
Researchers are conducting a phase 1b/2 trial to test tucatinib plus alpelisib in patients with advanced, PIK3CA -mutant, HER2+ breast cancer.
Researchers are conducting a phase 1 trial to test CAR T-cell therapy in patients with mesothelin-expressing triple-negative breast cancer.
Non-frail patients with early-stage breast cancer have an increased risk of worsening frailty status after locoregional therapy, a study suggests.
The mean time to resolution of axillary lymphadenopathy after a COVID-19 vaccine booster is 102 days, according to a study.
Updated results support the use of adjuvant paclitaxel and trastuzumab in small, node-negative, HER2-positive breast cancer, according to researchers.
Alisertib monotherapy has shown activity in postmenopausal patients with endocrine-resistant, HER2-negative, metastatic breast cancer, but it was not able to restore sensitivity to fulvestrant in this patient population.
The risk of cancer remains high for women older than 50 years with BRCA1 or BRCA2 mutations, a study suggests.
Updated regulations require mammography facilities to notify patients about the density of their breasts.
COVID-19 vaccination may reduce the risk of COVID-19 sequelae in patients with cancer, according to researchers.
TNBC incidence rates ranged from less than 7 per 100,000 among Asian and Pacific Islander patients to more than 29 per 100,000 among Black patients.
Anatomic stage and receptor status influence the timing of recurrence for patients with local-regional breast cancer, a study suggests.
The FDA has expanded the approval of Verzenio (abemaciclib) plus endocrine therapy, removing the Ki-67 score requirement for patient selection.
There are “minimal prognostic differences” between HER2-low breast cancer and HER2-negative breast cancer, according to researchers.
Artificial intelligence can predict survival in cancer patients using information from a patient’s initial consultation with an oncologist, a study suggests.
Load More